869 related articles for article (PubMed ID: 13958)
21. Clinical pharmacology of adrenergic-adrenoreceptor-blocking drugs.
Louis WJ; Taylor H; McNeil JJ; Jarrott B; Rand MJ
Am Heart J; 1982 Aug; 104(2 Pt 2):407-12. PubMed ID: 6125097
[TBL] [Abstract][Full Text] [Related]
22. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.
Frishman WH; Alwarshetty M
Clin Pharmacokinet; 2002; 41(7):505-16. PubMed ID: 12083978
[TBL] [Abstract][Full Text] [Related]
23. Balanced pharmacokinetics and metabolism of bisoprolol.
Leopold G
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S16-20. PubMed ID: 2439789
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics in the elderly.
Crooks J; O'Malley K; Stevenson IH
Clin Pharmacokinet; 1976; 1(4):280-96. PubMed ID: 797500
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetics of cholinesterase inhibitors.
Aquilonius SM; Hartvig P
Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic implications for the clinical use of propofol.
Kanto J; Gepts E
Clin Pharmacokinet; 1989 Nov; 17(5):308-26. PubMed ID: 2684471
[TBL] [Abstract][Full Text] [Related]
27. Influence of smoking and age on pharmacokinetics of beta-receptor blockers.
Hitzenberger G; Fitscha P; Beveridge T; Nüesch E; Pacha W
Gerontology; 1982; 28 Suppl 1():93-100. PubMed ID: 6123470
[TBL] [Abstract][Full Text] [Related]
28. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
29. Absolute bioavailability study in the dog with Visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity.
McAinsh J; Smith RP; Ferguson RA
Eur J Drug Metab Pharmacokinet; 1984; 9(2):129-39. PubMed ID: 6146530
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of propranolol: a review.
Shand DG
Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
[TBL] [Abstract][Full Text] [Related]
31. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.
Klotz U
Clin Pharmacokinet; 1976; 1(3):204-18. PubMed ID: 797498
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
Grevel J
J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
[TBL] [Abstract][Full Text] [Related]
33. The clinical pharmacokinetics of levofloxacin.
Fish DN; Chow AT
Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
[TBL] [Abstract][Full Text] [Related]
34. Calcium antagonists. Pharmacokinetic properties.
Kates RE
Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker.
Carruthers SG; Pentikainen P; Hosler JP; Azarnoff DL
Clin Pharmacol Ther; 1979 Dec; 26(6):682-5. PubMed ID: 40725
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics of rifampicin.
Acocella G
Clin Pharmacokinet; 1978; 3(2):108-27. PubMed ID: 346286
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of candesartan.
Gleiter CH; Mörike KE
Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics of cyclosporin.
Ptachcinski RJ; Venkataramanan R; Burckart GJ
Clin Pharmacokinet; 1986; 11(2):107-32. PubMed ID: 3514043
[TBL] [Abstract][Full Text] [Related]
39. Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.
Park BK
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):3S-10S. PubMed ID: 6146338
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of ranitidine.
Roberts CJ
Clin Pharmacokinet; 1984; 9(3):211-21. PubMed ID: 6329583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
